Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Needham downgrades Personalis to Hold after $1.5B Tempus AI acquisition deal announced
TEM
$54.87
+$2.82 +5.42%

Needham downgrades Personalis to Hold after $1.5B Tempus AI acquisition deal announced

Market News
20 Jul 2026
Alex Lavoie
View Source
Bearish
pluang ai news

Personalis, a cancer testing firm, is being acquired by Tempus AI in a $1.5 billion all-stock deal offering $16.25 per share, a 28% premium. Despite the premium, Personalis shares dropped 13.39% on the announcement day due to capped upside until deal closure. Analyst firm Needham downgraded Personalis from Buy to Hold, citing limited potential gains. The stock's future now depends on the successful completion of the acquisition by Tempus AI.

More News (TEM)

CellCarta partners with Tempus to boost oncology companion diagnostic access in the US.

CellCarta partners with Tempus to boost oncology companion diagnostic access in the US.

CellCarta announced a strategic partnership with Tempus AI to enhance its CDx Commercialization Lab Network, focusing on oncology companion diagnostics. This collaboration allows biopharma sponsors a streamlined path from diagnostic development and r...

Market News
Bullish
4 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App